High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
0 Analyst Rating
Wall Street analysts forecast 00388.HK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00388.HK is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 404.000
Low
Averages
High
Current: 404.000
Low
Averages
High
HSBC
HSBC Global Research
maintain
$530
2025-11-13
Reason
HSBC
HSBC Global Research
Price Target
$530
2025-11-13
maintain
Reason
The analyst rating from HSBC Global Research for HKEX is based on the belief that the acquisition of a 20% stake in CMU OmniClear Holdings for $455 million is a positive move for the company. They noted that while the transaction will have a limited short-term financial impact, the commercialization of CMU OmniClear could provide upside potential. Additionally, HKEX's history of driving market development through financial infrastructure enhancements suggests a promising growth potential for its financial innovation center business. As a result, HSBC maintained a "Buy" rating with a target price of $530.
DBS Research
DBS Research
Buy
maintain
$540
2025-11-07
Reason
DBS Research
DBS Research
Price Target
$540
2025-11-07
maintain
Buy
Reason
DBS Research has issued a Buy rating on HKEX due to several positive factors: strong momentum in the Hong Kong bourse, improved liquidity and investment sentiment, attractive valuations of Hong Kong tech stocks compared to other markets, and supportive government policies and stimulus measures. They have also raised their average daily turnover forecast for HKEX, indicating confidence in the market's performance. The target price remains at HKD540.
UOB Kay Hian
UOB Kay Hian
Buy
maintain
$548
2025-11-07
Reason
UOB Kay Hian
UOB Kay Hian
Price Target
$548
2025-11-07
maintain
Buy
Reason
The analyst rating from UOB Kay Hian for HKEX is a "Buy" due to a significant 56% year-over-year increase in net profit for 3Q25, which exceeded the broker's expectations by 7%. This strong performance was attributed to robust growth in core revenue, a record-breaking average daily trading volume, and strong IPO momentum. Despite a decline in net interest income, the overall positive financial results led to the decision to maintain a Buy rating and raise the target price to HKD548.
CICC
CICC
Outperform
maintain
$500
2025-11-07
Reason
CICC
CICC
Price Target
$500
2025-11-07
maintain
Outperform
Reason
The analyst rating from CICC for HKEX (00388.HK) is maintained at "Outperform" with a target price of $500 due to the company's strong financial performance in the third quarter of 2025. The total revenue grew by 45% year-over-year to $7.775 billion, and profit increased by 56% year-over-year to $4.9 billion, which exceeded market expectations. This growth was attributed to the rapid expansion of market-related businesses driven by active trading and solid investment income. CICC's forecasts for 2025-2026 earnings remain largely unchanged, supporting their positive outlook and indicating an 18% upside potential based on the target price.
Goldman Sachs
Goldman Sachs
Buy
maintain
$544 -> $562
2025-11-06
Reason
Goldman Sachs
Goldman Sachs
Price Target
$544 -> $562
2025-11-06
maintain
Buy
Reason
Goldman Sachs maintained a Buy rating on HKEX due to its 3Q25 earnings exceeding expectations, driven by strong investment income and a significant increase in average daily turnover. The firm raised its target price from HKD544 to HKD562, citing three key factors for the positive outlook: upward revisions in market consensus for daily turnover forecasts, an expansion of HKEX's price-to-earnings premium relative to the HSI and HSTECH, and a recovery in the growth momentum of Hong Kong-listed companies.
JPMorgan
Overweight
maintain
$530
2025-11-05
Reason
JPMorgan
Price Target
$530
2025-11-05
maintain
Overweight
Reason
The analyst rating for HKEX (00388.HK) has been kept as Overweight due to several key factors highlighted in JPMorgan's research report. The company's 3Q25 net profit increased significantly by 56% year-over-year and 10% quarter-over-quarter, surpassing the broker's estimates. This strong performance was driven by better-than-expected clearing and settlement income, with overall revenue exceeding forecasts by 1%. Additionally, expenses were lower than anticipated, contributing to a higher operating profit margin.
Despite the robust trading volumes and positive financial results, HKEX's stock price has been declining, which JPMorgan views as a divergence from the strong fundamental drivers, particularly trading volume. This situation is expected to create conditions for a potential price rally in the coming months. As a result, JPMorgan maintains an Overweight rating with a target price of HKD530, anticipating upward revisions in HKEX's market valuation.
See All Ratings
Valuation Metrics
The current forward P/E ratio for HKEX (00388.HK) is 0.00, compared to its 5-year average forward P/E of 0.36. For a more detailed relative valuation and DCF analysis to assess HKEX 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.36
Current PE
0.00
Overvalued PE
4.05
Undervalued PE
-3.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
12.10
Current EV/EBITDA
9.24
Overvalued EV/EBITDA
21.69
Undervalued EV/EBITDA
2.50
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
20.37
Current PS
19.00
Overvalued PS
25.33
Undervalued PS
15.40
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
00388.HK News & Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/332a10b20e0a82f778f1fd2d9ec77d57d7a4d53beabbe969ca1efe1f9538d0e9.jpg)
Preview
8.5
09:02 AMaastocksPinnedHKEX IPO Fundraising Increases Approximately 2.3 Times Year-Over-Year in 11M25
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/53377e8f0ca8d8744277039ea2a05bc5ad6d4d2355cd14c1d1f55c74b200229b.jpg)
Preview
4.0
10:39 AMaastocksM Stanley's Selected Stocks for Hong Kong and China (Table)
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/4ab9592fd24834cdee8a84ed4c1f673e8b7faead6a5ea677c10d76220ad950cc.jpg)
Preview
8.5
12-04aastocksHK Achieves 91 IPOs in 11M25, Raising Approximately $260B and Leading Globally
Sign Up For More News
People Also Watch
FAQ
What is HKEX (00388.HK) stock price today?
What is HKEX (00388.HK)'s business?
What is the price predicton of 00388.HK Stock?
What is HKEX (00388.HK)'s revenue for the last quarter?
What is HKEX (00388.HK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for HKEX (00388.HK)'s fundamentals?
How many employees does HKEX (00388.HK). have?